{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Macular+Degeneration+%28Age+Related%29&page=2",
    "query": {
      "condition": "Macular Degeneration (Age Related)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Macular+Degeneration+%28Age+Related%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T12:22:04.813Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04864834",
      "title": "Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "SOK583A1 (40 mg/mL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Eylea EU (40 mg/mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sandoz",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 485,
      "start_date": "2021-05-12",
      "completion_date": "2023-05-10",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Campbell, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04864834"
    },
    {
      "nct_id": "NCT02484690",
      "title": "A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 273,
      "start_date": "2015-08-11",
      "completion_date": "2017-09-26",
      "has_results": true,
      "last_update_posted_date": "2020-11-12",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02484690"
    },
    {
      "nct_id": "NCT01997164",
      "title": "Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (\"Wet\") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "REGN910-3",
          "type": "DRUG"
        },
        {
          "name": "REGN910",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-11",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-01-12",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Winter Haven, Florida • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "West Columbia",
          "state": "South Carolina"
        },
        {
          "city": "Abilene",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01997164"
    },
    {
      "nct_id": "NCT05110209",
      "title": "Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "OTHER"
        },
        {
          "name": "Ranibizumab",
          "type": "OTHER"
        },
        {
          "name": "Bevacizumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 331541,
      "start_date": "2020-07-15",
      "completion_date": "2020-11-20",
      "has_results": false,
      "last_update_posted_date": "2021-12-21",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05110209"
    },
    {
      "nct_id": "NCT00101764",
      "title": "Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Degeneration",
        "Retinal Vein Occlusion",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2005-01-05",
      "completion_date": "2008-05-20",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101764"
    },
    {
      "nct_id": "NCT04437368",
      "title": "EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "GT005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gyroscope Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2019-04-26",
      "completion_date": "2024-04-05",
      "has_results": true,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04437368"
    },
    {
      "nct_id": "NCT02137915",
      "title": "Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "Human Central Nervous System Stem Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "StemCells, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "51 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2014-04",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-02",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02137915"
    },
    {
      "nct_id": "NCT00492284",
      "title": "Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "verteporfin",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QLT Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 162,
      "start_date": "2007-07",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2011-06-02",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 21,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492284"
    },
    {
      "nct_id": "NCT04643886",
      "title": "A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Age-related Macular Degeneration",
        "Geographic Atrophy",
        "Macular Degeneration",
        "Retinal Disease",
        "Retinal Degeneration"
      ],
      "interventions": [
        {
          "name": "GEM103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gemini Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2020-07-30",
      "completion_date": "2022-03-21",
      "has_results": false,
      "last_update_posted_date": "2022-09-23",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04643886"
    },
    {
      "nct_id": "NCT03468296",
      "title": "Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tennessee Retina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2018-04",
      "completion_date": "2019-07",
      "has_results": false,
      "last_update_posted_date": "2018-04-20",
      "last_synced_at": "2026-06-10T12:22:04.813Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03468296"
    }
  ]
}